XML 52 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details) - USD ($)
1 Months Ended
Dec. 31, 2023
Jun. 30, 2024
Dec. 11, 2023
Sep. 30, 2023
Jun. 30, 2023
Nov. 22, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Contract liabilities   $ 0   $ 866,000    
GSK | GSK-HSD License Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Milestone payment receivable         $ 30,000,000  
Milestone payment receivable upon achievement of phase two and first patient dosed in phase three           $ 100,000,000.0
GSK | GSK-HSD License Agreement | Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Commercial milestone payments at first commercial sale           190,000,000.0
Sales-related milestone payments           $ 590,000,000.0
GSK | GSK-HBV Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Initial transaction price $ 2,700,000          
Contract assets   0        
Contract liabilities   $ 0        
GSK | GSK-HBV Agreement | Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Development and sales milestone payments     $ 832,500,000